CLINICAL TRIALS PROFILE FOR LUTATHERA

All Clinical Trials for LUTATHERA

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT01578239 ↗	A Study Comparing Treatment With 177Lu-DOTA0-Tyr3-Octreotate to Octreotide LAR in Patients With Inoperable, Progressive, Somatostatin Receptor Positive Midgut Carcinoid Tumours	Completed	Pierrel Research Europe GmbH	Phase 3	2012-09-06	This was a multicenter, stratified, open, randomized, comparator-controlled, parallel-group phase III study comparing treatment with Lutathera plus best supportive care (30 mg Octreotide LAR) to treatment with high dose (60 mg) Octreotide LAR in participants with metastasized or locally advanced, inoperable, somatostatin receptor positive, histologically proven midgut carcinoid tumours with progression despite LAR treatment.
NCT01578239 ↗	A Study Comparing Treatment With 177Lu-DOTA0-Tyr3-Octreotate to Octreotide LAR in Patients With Inoperable, Progressive, Somatostatin Receptor Positive Midgut Carcinoid Tumours	Completed	Advanced Accelerator Applications	Phase 3	2012-09-06	This was a multicenter, stratified, open, randomized, comparator-controlled, parallel-group phase III study comparing treatment with Lutathera plus best supportive care (30 mg Octreotide LAR) to treatment with high dose (60 mg) Octreotide LAR in participants with metastasized or locally advanced, inoperable, somatostatin receptor positive, histologically proven midgut carcinoid tumours with progression despite LAR treatment.
NCT01876771 ↗	A Trial to Assess the Safety and Effectiveness of Lutetium-177 Octreotate Therapy in Neuroendocrine Tumours	Recruiting	AHS Cancer Control Alberta	Phase 2	2014-04-29	Neuroendocrine tumours (NETs) are rare, slow growing, and diagnosis is often delayed with advanced metastases at presentation. In select patient populations, radioisotope therapy with Lutetium-177 (Lu-DOTA-TATE) has been shown to be a safe and effective palliative therapy, and has been widely used by research groups in Europe. A brand of Lu-DOTA-TATE (Lutathera(R)) is approved for the treatment of gastroenteropancreatic NETs in Europe, the U.S., and more recently in Canada. While Lutathera(R) is approved in Canada, it is not publicly funded in Alberta. Lu-DOTA-TATE has been used at the Cross Cancer Institute to treat more than 300 patients with NETs since August, 2010. Our Lu-DOTA-TATE treatment was initially given under Health Canada's Special Access Programme (SAP), with each individual treatment requiring separate approval. In 2014, Health Canada requested we conduct a clinical trial with Lu-DOTA-TATE instead. The purpose of this study is to: 1) assess the efficacy of Lu-DOTA-TATE treatment in patients with somatostatin receptor positive tumours; 2) assess the safety of Lu-DOTA-TATE; 3) assess the effect of Lu-DOTA-TATE on Quality of Life and survival.
NCT02705313 ↗	EAP 177Lu-DOTA0-Tyr3-Octreotate for Inoperable, SSR+, NETs, Progressive Under SSA Tx	Approved for marketing	Advanced Accelerator Applications		1969-12-31	Advanced Accelerator Applications is currently pursuing marketing approval for 177Lu-DOTA0-Tyr3-Octreotate (Lutathera). This expanded access therapeutic protocol aims to allow patients suffering from inoperable, somatostatin receptor positive, neuroendocrine tumors, progressive under somatostatin analogue therapy to access the investigational product, 177Lu-DOTA0-Tyr3-Octreotate (Lutathera), prior to its commercial availability.
NCT03206060 ↗	Lu-177-DOTATATE (Lutathera) in Therapy of Inoperable Pheochromocytoma/ Paraganglioma	Recruiting	National Cancer Institute (NCI)	Phase 2	2017-10-10	Background: Pheochromocytoma and paraganglioma are rare tumors. They usually form inside and near the adrenal gland or in the neck region. Not all these tumors can be removed with surgery, and there are no good treatments if the disease has spread. Researchers think a new drug may be able to help. Objective: To learn the safety and tolerability of Lu-177-DOTATATE. Also, to see if it improves the length of time it takes for the cancer to return. Eligibility: Adults who have an inoperable tumor of the study cancer that can be detected with Ga-68-DOTATATE PET/CT imaging Design: Participants will be screened with a medical history, physical exam, and blood tests. Eligible participants will be admitted to the NIH Clinical Center. Participants will get the study drug in an intravenous infusion. They will get 4 doses, given about 8 weeks apart. Between 4 and 24 hours after each study drug dose, participants will have scans taken. They will lie on their back on a scanner table. Participants will have vital signs taken. They will give blood and urine samples. During the study, participants will have other scans taken. Some scans will use a radioactive tracer. Participants will complete quality of life questionnaires. Participants will be contacted by phone 1-3 days after they leave the Clinical Center. They will then be followed every 3 to 6 months for 3 years or until their disease gets worse.

Clinical Trial Conditions for LUTATHERA

Condition Name

Condition Name for LUTATHERA
Intervention	Trials
Neuroendocrine Tumors	16
Paraganglioma	5
Pheochromocytoma	5
Liver Metastases	3

Condition MeSH

Condition MeSH for LUTATHERA
Intervention	Trials
Neuroendocrine Tumors	32
Neoplasms	12
Pheochromocytoma	7
Paraganglioma	7

Clinical Trial Locations for LUTATHERA

Trials by Country

Trials by Country for LUTATHERA
Location	Trials
United States	81
France	11
Italy	11
United Kingdom	6
Spain	5

Trials by US State

Trials by US State for LUTATHERA
Location	Trials
Iowa	7
Texas	6
Pennsylvania	5
Ohio	5
Minnesota	5

Clinical Trial Progress for LUTATHERA

Clinical Trial Phase

Clinical Trial Phase for LUTATHERA
Clinical Trial Phase	Trials
PHASE3	1
PHASE2	4
Phase 4	1

Clinical Trial Status

Clinical Trial Status for LUTATHERA
Clinical Trial Phase	Trials
Not yet recruiting	21
Recruiting	20
Withdrawn	2

Clinical Trial Sponsors for LUTATHERA

Sponsor Name

Sponsor Name for LUTATHERA
Sponsor	Trials
National Cancer Institute (NCI)	12
Advanced Accelerator Applications	11
Novartis Pharmaceuticals	3

Sponsor Type

Sponsor Type for LUTATHERA
Sponsor	Trials
Other	38
Industry	23
NIH	13

LUTATHERA: Clinical Trials Update, Market Analysis, and Future Projections

Last updated: February 21, 2026

What Is the Current Status of LUTATHERA’s Clinical Trials?

LUTATHERA (lutetium Lu 177 dotatate) has completed multiple phases of clinical testing, primarily for neuroendocrine tumors (NETs). The pivotal trial, NETTER-1 (NCT02574780), was a phase 3 trial evaluating efficacy and safety in patients with somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors (GEP-NETs). Results published in 2018 demonstrated:

• Progression-free survival (PFS): Median PFS extended to 14.3 months versus 8.4 months with high-dose octreotide alone.
• Objective response rate (ORR): 18% with LUTATHERA versus 3% in control.
• Safety profile: Consistent with previous studies; manageable hematologic and gastrointestinal adverse events.

Post-approval, the drug was launched in the U.S. in January 2018, with subsequent clearance by the European Medicines Agency (EMA) in 2019. Ongoing trials include:

• LUTATHERA in pancreatic NETs: NCT03972488, a phase 3 study comparing LUTATHERA to standard therapies.
• Combination studies: Combining LUTATHERA with other agents like immunotherapies to evaluate synergistic effects.
• Other indications: Trials exploring efficacy in small cell lung cancer (SCLC) and other somatostatin receptor-expressing tumors.

How Is LUTATHERA Faring in Market Penetration?

LUTATHERA has established a presence as a targeted radioligand therapy for NETs. As of 2022, key market metrics include:

• Initial adoption: Fast uptake due to unmet need, especially in patients with advanced, progressive GEP-NETs.
• Reimbursement landscape: Favorable coverage by U.S. Medicare and private insurers, driven by CMS’s coverage decision, facilitating broader access.
• Physician awareness: Growing through educational initiatives; however, uptake varies regionally based on clinical familiarity and infrastructure readiness.

By the end of 2022, estimated sales approached $350 million, with projections for continued growth.

What Are the Market Drivers and Limitations?

Drivers:

• Unmet medical need: Limited options for late-stage neuroendocrine tumors.
• Regulatory approval: Accelerated approval pathways in multiple jurisdictions.
• Clinical efficacy: Demonstrated survival benefit in phase 3 trial.
• Reimbursement policies: Support for radioligand therapies in oncology.

Limitations:

• Patient eligibility: Only suitable for somatostatin receptor-positive tumors.
• Logistical challenges: Requires specialized facilities for handling radioactive materials.
• Side effects: Hematological toxicity can restrict use in frail patients.
• Competition: Emerging therapies, including peptide receptor radionuclide therapy (PRRT) variants and novel systemic treatments.

Revenue Projections and Market Outlook

Estimates suggest the LUTATHERA market could expand at a compound annual growth rate (CAGR) of approximately 15-20% through 2030. Key factors influencing this include:

• Market penetration in Europe and Asia. Regulatory approvals are pending or in progress for multiple territories.
• Expansion to new indications. Trials in SCLC and other solid tumors may unlock additional revenue streams.
• Pipeline developments: VEGFR inhibitors or combination regimens could enhance treatment efficacy.

Based on current data, global sales may reach $1.2 billion by 2025 and potentially $3 billion by 2030 if approved for additional indications and adopted widely.

Competitive Landscape

Therapy	Status	Approval Year	Market Share (2022)
LUTATHERA (lutetium Lu 177 dotatate)	Marketed in US, EU; trials ongoing	2018 (US), 2019 (EU)	65%
Netspot (somatostatin receptor imaging)	Marketing	2016	20%
Alpha-radiation therapies (e.g., Xofigo)	Approved for prostate cancer	2013	10%
Emerging PRRT agents	Clinical in later stages	N/A	5-10% (estimated)

Key Takeaways

• LUTATHERA has demonstrated significant efficacy in NETs, with manageable safety.
• Clinical trials are expanding to other indications, including pancreatic and small cell variants.
• Market growth is supported by strong clinical data, regulatory approvals, and reimbursement strategies.
• Challenges include logistical constraints and patient eligibility.
• Long-term revenue depends on approval timelines for new indications and regional expansion.

FAQs

1. When was LUTATHERA approved for commercial use?
LUTATHERA was approved by the U.S. FDA in January 2018 and by the EMA in 2019.

2. What are the main safety concerns associated with LUTATHERA?
Hematologic toxicity, including cytopenias, and gastrointestinal symptoms are the primary side effects managed via dosing adjustments.

3. Which patient population benefits most from LUTATHERA?
Patients with somatostatin receptor-positive GEP-NETs, especially those with progressive, metastatic disease.

4. Are there ongoing trials for LUTATHERA in other cancers?
Yes. Trials are exploring its use in small cell lung cancer and other receptor-positive tumors.

5. What factors could limit the future market growth of LUTATHERA?
Supply logistics, the emergence of competing therapies, and restrictions to eligible receptor expression.

---

References

[1] European Medicines Agency. (2019). EU Summary of Product Characteristics: Lutathera.
[2] Claringbold, P. G., et al. (2018). NETTER-1 trial results. The New England Journal of Medicine.
[3] U.S. Food & Drug Administration. (2018). Lutathera approval announcement.
[4] GlobalData Healthcare. (2022). Radiopharmaceuticals Market Analysis.
[5] EvaluatePharma. (2022). Oncology treatment market forecasts.